Theragenics to Report Second Quarter 2013 Financial Results on August 8, 2013
06 Août 2013 - 1:14PM
Business Wire
Theragenics Corporation® (NYSE: TGX) expects to release second
quarter 2013 financial results before the market opens on August 8,
2013. As a result of the merger agreement with Juniper Investment
Company, LLC, announced August 5, 2013, management of Theragenics
will not be hosting a conference call.
Theragenics Corporation (NYSE: TGX) operates two business
segments: its surgical products business and its brachytherapy seed
business. The surgical products business (www.cpmedical.com,
www.galtmedical.com, www.needletech.com) manufactures and
distributes wound closure, vascular access, and specialty needle
products. Wound closure products include sutures, needles and other
surgical products. Vascular access includes introducers, guidewires
and related products. Specialty needles include coaxial, biopsy,
spinal and disposable veress needles, access trocars, implanters,
introducer products, and other needle-based products. The surgical
products segment serves a number of markets and applications,
including, among other areas, interventional cardiology,
interventional radiology, vascular surgery, orthopedics, plastic
surgery, dental surgery, urology, veterinary medicine, pain
management, endoscopy, and spinal surgery. Theragenics’
brachytherapy business manufactures, custom loads, distributes and
markets “seeds” used primarily in the minimally invasive treatment
of localized prostate cancer. The Company’s brachytherapy product
line (www.theragenicsbrachy.com) includes its palladium-103
TheraSeed® device and its iodine-125 AgX100® device. The terms
"Company," "we," "us," or "our" mean Theragenics Corporation and
all entities included in our consolidated financial statements. For
additional information, call our Investor Relations Department at
(800) 998-8479 or visit www.theragenics.com.
Additional Information and Where to Find It
In connection with the proposed transaction, the Company will
file a proxy statement with the SEC. INVESTORS ARE STRONGLY ADVISED
TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED
WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ON THE PROPOSED TRANSACTION. Investors may
obtain free of charge the proxy statement (when available) and
other relevant documents filed with the SEC with respect to the
proposed transaction at the SEC’s website at www.sec.gov. In
addition, the proxy statement (when available) and such other
documents may be obtained free of charge by directing a request to
Theragenics Corporation, 5203 Bristol Industrial Way, Buford,
Georgia 30518, Attention: Investor Relations Department, (800)
998-8479.
The Company and its directors, executive officers and certain
other members of its management and employees may be deemed to be
participants in the solicitation of proxies from its stockholders
in connection with the proposed merger. Information regarding the
interests of such directors and executive officers is included in
the Company’s proxy statement for its 2013 Annual Meeting of
Stockholders filed with the SEC on April 1, 2013, and information
concerning all of the Company’s participants in the solicitation
will be included in the proxy statement related to the proposed
merger when it becomes available.
Theragenics CorporationFrank J. Tarallo, 800-998-8479 or
770-271-0233CFO & TreasurerorLisa Rassel, 800-998-8479 or
770-271-0233Investor Relations Managerwww.theragenics.com
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024